Glioblastoma multiforme is a devastating brain cancer type in adults. Credit: Pete Linforth from Pixabay.

Researchers from the University of Surrey have showed in a study that a short chain of amino acids, HTL-001 peptide, is effective for target and inhibition of the function of Hox genes that causes growth of glioblastoma multiforme (GBM). 

These findings are obtained from a seven-year research project carried out in cell and animal models.  

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The project was conducted in partnership with the universities of Surrey, Leeds and Texas and HOX Therapeutics.

HOX Therapeutics, the University of Surrey’s start-up firm, is in the Surrey Research Park.

The HTL-001 peptide analysed in the study has been tested for safety and is claimed to be fit for subject trials. 

See Also:

Currently, these trials are being explored to treat GBM and other cancers. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A family of genes, Hox genes are crucial for proper brain tissue growth but are usually silenced at birth following robust activity in the developing embryo. 

However, if they are ‘switched on’ again incorrectly, their activity can cause cancer progression. 

Dysregulation of Hox gene has been associated with GBM.  

University of Surrey Medical Oncology professor and project lead Hardev Pandha said: “People who suffer from Glioblastoma Multiforme have a five per cent survival rate over a five-year period – a figure that has not improved in decades. 

“While we are still early in the process, our seven-year project offers a glimmer of hope for finding a solution to Hox gene dysregulation, which is associated with the growth of GBM and other cancers, and which has proven to be elusive as a target for so many years.” 

GBM is a common and devastating kind of brain cancer in adults.